Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nada Abou Fayssal

Neurology Brooklyn, NY Medical Doctor

NPI 1225095292 CMS profile 100506

186 Joralemon St, Brooklyn, NY 11201

Open in the dashboard

General payments

$141,248

419 records reported · program years 2019–2025

Research payments

$1,694

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$77,586 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Nada Abou Fayssal of Brooklyn, NY is reported in the CMS Open Payments database as having received $141,248 across 419 general payments and $1,694 in research payments paid to them. Separately, studies naming them as principal investigator received $77,586 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,933 102
2024 General $62,640 111
2023 General $12,907 77
2022 General $979 41
2021 General $1,542 32
2020 General $427 10
2019 General $24,820 46
2019 Research $1,694 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nada Abou Fayssal
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Nada Abou Fayssal were reported at $37,933. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Nada Abou Fayssal Neurology median Middle half National median
2019 $24,820 $474 $118–$2,177 $163
2020 $427 $367 $82–$2,309 $114
2021 $1,542 $438 $104–$2,547 $132
2022 $979 $442 $103–$2,388 $149
2023 $12,907 $464 $119–$2,312 $160
2024 $62,640 $468 $119–$2,323 $164
2025 $37,933 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $106,254 103 payments
  2. Novartis Pharmaceuticals Corporation $17,088 76 payments
  3. Genzyme Corporation $9,149 21 payments
  4. Ares Trading SA $2,400 1 payment
  5. Biogen, Inc. $1,353 42 payments
  6. AbbVie, Inc. $1,289 66 payments
  7. Banner Life Sciences, LLC $900 1 payment
  8. Celgene Corporation $551 24 payments
  9. Amgen Inc. $257 12 payments
  10. Janssen Pharmaceuticals, Inc $205 9 payments
  11. Other $1,801 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $85,287 26 payments
  2. Consulting Fee $25,111 5 payments
  3. Travel and Lodging $19,103 40 payments
  4. Food and Beverage $10,556 342 payments
  5. Honoraria $900 1 payment
  6. Education $217 3 payments
  7. Gift $75 2 payments
Products named General payments · program years 2019–2025
  1. Mavenclad Neurology $61,823 40 payments
  2. MAYZENT $12,590 13 payments
  3. AUBAGIO $8,895 12 payments
  4. BAFIERTAM $900 1 payment
  5. BOTOX $720 44 payments
  6. VUMERITY $651 16 payments
  7. MAVENCLAD Neurology $598 12 payments
  8. KESIMPTA $560 37 payments
  9. ZEPOSIA $498 22 payments
  10. TYSABRI $458 23 payments
  11. Other $3,613 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. EMD Serono, Inc. $1,694 13 payments

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

978

Median for Neurology: 833

Drug cost

$1,079,396

Median for Neurology: $202,670

Branded share of claims

33.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gilenya Fingolimod Hcl Brand 23 $230,542
Tecfidera Dimethyl Fumarate Brand 24 $223,045
Copaxone Glatiramer Acetate Brand 25 $153,538
Ampyra Dalfampridine Brand 22 $147,135
Avonex (4 Pack) Interferon Beta-1a Brand 13 $124,805
Vumerity Diroximel Fumarate Brand 12 $94,127
Teriflunomide Generic 55 $29,923
Dalfampridine Er Dalfampridine Brand 76 $19,336
Nurtec Odt Rimegepant Sulfate Brand 19 $19,025
Aimovig Autoinjector Erenumab-Aooe Brand 13 $9,169

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$55,925

Of which drugs: $32,714

Medicare patients

124

Average age 70

Services billed

3,690

70 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 44%
Ischemic heart disease 32%
Depression 32%
Alzheimer's or dementia 30%
Chronic kidney disease 26%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, baclofen, 10 mg J0475 Office 12 126 $16,670

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Mavenclad
$29,423 — —
BOTOX
$515 — —
KESIMPTA
$198 — —
BRIUMVI
$106 — —
Leqembi
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

432 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record